Literature DB >> 8543941

Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.

J O Rinne1, A Laihinen, H Ruottinen, U Ruotsalainen, K Någren, P Lehikoinen, V Oikonen, U K Rinne.   

Abstract

Striatal dopamine D2 receptors were studied, using positron emission tomography (PET), in 10 patients with early Parkinson's disease without any antiparkinsonian medication and in 14 healthy controls. [11C]Raclopride was used as ligand and an equilibrium method was applied. The maximum count of receptors (Bmax) and their dissociation constant (Kd) were calculated according to the Scatchard principle. In parkinsonian patients, the Bmax of D2 receptors was increased in the putamen contralateral to the predominant symptoms, as compared to the opposite putamen, by 33% (p = 0.0008). In the caudate nucleus no significant side to side differences was noted. On comparison with age-matched healthy controls, Bmax values in the putamen (p = 0.0012) but not in the caudate nucleus contralateral to the side of predominant clinical symptoms were increased in PD patients. The Kd values were unchanged. The difference in putaminal Bmax values between the opposite hemispheres correlated with the difference in the severity of parkinsonian motor symptoms between the two body sides (r = 0.69, p = 0.03). The present results show that there is both a relative and absolute increase in the number of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543941     DOI: 10.1016/0022-510x(95)00137-q

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  28 in total

Review 1.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

Review 3.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

4.  Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography.

Authors:  Elissa M Strome; Ivan L Cepeda; Vesna Sossi; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

Review 5.  Neuroimaging and transcranial ultrasonography in Parkinson's disease.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

6.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

Review 7.  Positron emission tomography in Parkinson's disease: insights into impulsivity.

Authors:  Adam J Stark; Daniel O Claassen
Journal:  Int Rev Psychiatry       Date:  2017-12-05

8.  In vivo imaging of dopaminergic neurotransmission after transient focal ischemia in rats.

Authors:  Abraham Martín; Vanessa Gómez-Vallejo; Eneko San Sebastián; Daniel Padró; Irati Markuerkiaga; Irantzu Llarena; Jordi Llop
Journal:  J Cereb Blood Flow Metab       Date:  2012-11-14       Impact factor: 6.200

9.  Measurement of density and affinity for dopamine D(2) receptors by a single positron emission tomography scan with multiple injections of [(11)C]raclopride.

Authors:  Yoko Ikoma; Hiroshi Watabe; Takuya Hayashi; Yoshinori Miyake; Noboru Teramoto; Kotaro Minato; Hidehiro Iida
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

10.  An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.

Authors:  Florence Véronneau-Veilleux; Philippe Robaey; Mauro Ursino; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-21       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.